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ifferent Metabolic Effects of
elective and Nonselective
eta-Blockers Rather Than Mere
eart Rate Reduction May Be
he Mechanisms by Which
eta-Blockade Prevents
ardiovascular Events
e read with interest the article by Bangalore et al. (1), who
nalyzed in 9 trials the role of pharmacologic reduction of heart
ate (HR) using beta-blockers in preventing cardiovascular events
n patients with hypertension. Beta-blocker–induced lower HR
as associated with greater mortality and morbidity risk. As the
asis of worse outcomes with “beta-blockers,” the authors recog-
ize only an increase in central aortic/pulse pressure with pharma-
ologic HR lowering. Even though they acknowledge that the
eta-blocker used in the studies was mainly atenolol, and hence,
ny extrapolation of these results to other beta-blockers should be
one with caution, the whole paper and the accompanying
ditorial just generically refer to “beta-blockade.” In fact, the
echanisms by which beta-blockers improve prognosis in different
ardiac contexts are probably multiple. Improved energy efficiency
een with some beta-blockers (2) could be one of the reasons for
etter survival observed with their use (3). Additionally, central
nhibition of sympathetic activity with moxonidine in heart failure,
espite a significant reduction of HR, has been associated with
ncreased mortality (4). In fact, moxonidine has been shown to
lter myocardial metabolism (5). This could be the reason for the
ailure of central sympathetic inhibition to prevent deaths in
atients with heart failure and also indicates that the predominant
echanism of action of “effective” beta-blockers is probably related
o mechanisms other than mere HR reduction. In fact, apart from
educing HR, atenolol and most selective beta-blockers impair
ndothelial function, decrease insulin sensitivity, and increase lipid
evels (6), all conditions that may worsen the global risk profile.
onversely, new generation beta-blockers have been seen to
mprove metabolism and endothelial function (7). Therefore, HR
eduction in itself, especially if associated with a bulk of deleterious
etabolic and vascular effects, is definitely not enough to improve
rognosis. The alarm created by the Bangalore et al. (1) paper
hould be clearly confined to selective beta-blockers and not
enerically extended to the whole drug class.
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eta-Blockers and Hypertension
angalore et al. (1) state that unlike results from post-myocardial
nfarction and congestive heart failure studies, a beta-blocker–
nduced low heart rate (HR) in hypertension is associated with an
ncrease in death rate and cardiovascular (CV) events. This
onclusion is highly misleading.
In post-myocardial infarction and congestive heart failure studies,
he benefit from beta-1 blockade arises from decreased work of the
eart (via reduced HR and blood pressure), reduced ventricular
brillation risk, and a reduction in catecholamine-induced (beta-1)
ardiac necrosis and apoptosis (2); thus, intrinsic sympathomimetic
ctivity reduces efficacy (2). The situation with hypertension is
omplex, as diastolic hypertension in the young/middle-aged arises
rom a link with obesity (3) and high sympathetic nerve activity plus
aised cardiac output (2). In contrast, isolated systolic hypertension
rises in the elderly via a decrease in vascular compliance (3).
The 3 main contributor trials in the Bangalore et al. (1) study
ere the ASCOT (Anglo-Scandinavian Cardiac Outcomes),
IFE (Losartan Intervention for Endpoint Reduction in Hyper-
ension), and INVEST (International Verapamil SR Trandolapril
tudy) studies in elderly patients with hypertension, which in-
olved moderately beta-1 selective atenolol as the first-line choice.
tenolol does not improve vascular compliance (2), so it does not
ower central systolic pressure; indeed first-line atenolol slightly
ncreases central pressure (4), possibly linked to partial beta-2 block-
